- Home
- OPCH vs BLLN Comparison
OPCH vs BLLN Comparison
Compare OPCH & BLLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OPCH | BLLN |
|---|---|---|
| Founded | N/A | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9B | 5.0B |
| IPO Year | N/A | 2025 |
Fundamental Metrics
Financial Performance| Metric | OPCH | BLLN |
|---|---|---|
| Price | $32.21 | $88.86 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 6 |
| Target Price | $36.30 | ★ $137.83 |
| AVG Volume (30 Days) | ★ 1.8M | 203.4K |
| Earning Date | 10-30-2025 | 12-09-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 6.77 | N/A |
| EPS | ★ 1.27 | N/A |
| Revenue | ★ $5,530,491,000.00 | $254,136,000.00 |
| Revenue This Year | $15.08 | $97.80 |
| Revenue Next Year | $7.51 | $35.87 |
| P/E Ratio | $25.39 | ★ N/A |
| Revenue Growth | 15.79 | ★ 254.30 |
| 52 Week Low | $22.62 | $80.51 |
| 52 Week High | $35.53 | $138.70 |
Technical Indicators
Market Signals| Indicator | OPCH | BLLN |
|---|---|---|
| Relative Strength Index (RSI) | 56.66 | N/A |
| Support Level | $31.93 | N/A |
| Resistance Level | $32.67 | N/A |
| Average True Range (ATR) | 0.67 | 0.00 |
| MACD | -0.21 | 0.00 |
| Stochastic Oscillator | 34.94 | 0.00 |
Price Performance
Historical ComparisonAbout OPCH Option Care Health Inc.
Option Care Health Inc is the provider of home and alternate-site infusion services. It provides treatment for bleeding disorders, neurological disorders, heart failure, anti-infectives, and chronic inflammatory disorders among others.
About BLLN BillionToOne Inc.
BillionToOne Inc is a precision diagnostics company revolutionizing molecular testing with its patented Quantitative Counting Templates (QCT) platform. This technology enables ultrasensitive, single-molecule DNA quantification, making genetic testing more accurate, affordable, and accessible. The company serves prenatal screening and oncology markets with non-invasive tests that detect fetal genetic risks and monitor cancer therapy response.